Medical network - on July 27, recently, people club department announced a new round of drug price negotiations as a result, 36 kinds of drugs into the negotiations of the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue (2017 edition) "b range, the average reduction of 44%, up to 70%.
The new round of drug price negotiations resulted in 16 varieties of anti-tumor immune drugs, 22 of them, with an average decline of 52.99 percent, and the highest drop drug was herceptin, which reached 64.80 percent. Anti-tumor protein kinase inhibitors erlotini, sorafenib, lapatinib and apatinib decreased by an average of 44.83%.
Up to now, eight drugs have been put into health care for anti-tumor protein kinase inhibitors (tipinids), and four other drugs are ecclinib, dasatinib, gefitinib and imatinib. Among them, ecclinib and gefitinib are among the first countries to negotiate drug price negotiations. The analysis shows that the price of the negotiation of the drug is down 46.37 percent from 2016 to 2017.
Figure 1. National negotiations for the drug market in key urban public hospitals in the 2010-2016 countries
Figure 2 price comparison chart (unit: yuan) before and after negotiation of the national negotiation of six anti-tumor drugs in anti-tumor
An overview of more than half of the "tienes" has been covered
CFDA medicine economic research institute, south China city public hospital chemical medicine terminal monitoring and analysis system (HDM) according to the latest figures, in 2016, China's key cities public hospital drug use total amount is RMB 130.637 billion yuan, year-on-year growth of 9.81% a year, compared with 2015 increased by 3.49%. The antitumor immune class is 23.843 billion yuan, a year-on-year growth of 10.30% a year.
For his kind of small molecular targeted drugs is important in clinical antitumor drugs, in 2016, there have been 12 for kind of small molecular targeted drugs into the public hospital, key cities public hospital drug use amount is 1.482 billion yuan, a year-on-year growth of 6.58% a year. At present, there are eight antitumor drugs that have entered the health care directory, accounting for 85.59 percent of the total amount of the drug in the key urban public hospitals in China, to 1.12.69 billion yuan. The conservative forecast is that the domestic anti-tumor tini market will exceed 10 billion yuan in 2018.
varieties
With the development of domestic "tini" innovative drugs and the imitation development of foreign patented drugs, domestic "tini" drugs have entered the market. According to CFDA's official website, the approved anti-tumor small molecular targeted agents in China are ecclinib, apatinib, gefitinib, dasatinib and imatinib. To further observe the market performance of eight "tennis-type" drugs that have entered health care.
Ecatinib: the market is over a billion dollars
China's first with completely independent intellectual property rights of small molecules targeting antineoplastic drugs is zhejiang beida pharmaceutical research and development for ek (Icotinib), at the beginning of the "twelfth five-year" cleared the CFDA, used for advanced non-small cell lung cancer treatment, commodity called "kay beauty".
Ek for, is the national "11th five-year plan" and the "twelfth five-year" science and technology major projects of outstanding achievements, was a great breakthrough on independent research and development of new drugs, was awarded the national progress prize in science and technology award. Under the promotion of domestic "tini" clinical medicine, the situation of western drug monopoly market is gradually broken. Before the negotiation, the bid price was 3,040 yuan, and the price of the negotiation was RMB 1399, a decline of 54%.
According to the data of HDM system, the market of ecktini in China's key urban public hospitals in 2016 was 214 million yuan, up 12.11 percent from the previous year. The country has more than 1 billion yuan in drug use.
The company's 2016 ipo prospectus shows that in the three years between 2013 and 2015, eckinib's sales reached 2.558 billion yuan. Ecktini has maintained a high growth rate for the fourth consecutive year, with an average annual growth rate of 122%, and is expected to be the leader of the small-molecule target drug market for lung cancer in 2017.
Gefitney: the first copy has been listed
Gefitinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. In February 2005, the British astrazeneca small molecular target drug gephinib entered the Chinese market, and the commodity, known as yiruisha, was the leading target drug for lung cancer in China.
Antitumor targeting drugs have significant differences in sensitive populations. In particular, gefitinib showed a certain activity in EGFR mutation in patients with different ethnic lung cancer patients, whose efficacy exceeded the usual first-line chemotherapy. Studies have shown that it is possible for people with Oriental or never-smoking to extend their lives significantly.
Figure 3. The market value of gephinib market in key urban public hospitals in 2008-2016
According to the data of HDM system, the market of jinontiani, a public hospital in China, was 2.49 billion yuan in 2016, down 2.94% from the previous year. In the complicated situation of academic promotion and high drug price, the sales performance is still lingering and volatile. Through the national committee of planning the first drug price negotiations, the treatment for Nepal tablet (250 mg x 10) by negotiation before bid the lowest price 5240 yuan to 2358 yuan, down 55%, with the new medical insurance directory, would promote the market growth, achieve the result of the price for quantity.
In February 18, qilu pharmaceutical development, listed as China's "twelfth five-year" "major drug discovery major science and technology projects" is listed on the treatment of targeted drugs, goods r can be called Iraq, thus breaking the astrazeneca branded drug Yi Rui sand exclusive monopoly.
Erlotini: generics declare enthusiasm
Erlotini is roche's listed drug for non-small cell lung cancer treatment. In 2007, roche's erlotini was listed in China, with a commodity named trokka, for advanced non-small cell lung cancer, which is used in EGFR gene sensitive mutations. According to the data of HDM system, the market of erlotini in China's key urban public hospital in 2016 was 107 million yuan, down 17.37 percent year on year, and price competition restricted market growth.
Figure 4. The market value of the urban public hospital of erlotini in the major cities of 2008-2016
After the price negotiation, the price of erlotinib (150mg x 7) was reduced from 3220 yuan to 1365 yuan, a decline of 57.60%. According to the report, by the end of 2015, there were 19 companies get clinical approval of generic drugs, there are eight generic drugs manufacture application is under review and approval documents in the future market will be intense competition.
Imatinib: sharing the market
Novartis's imatinib in 2002 to enter the Chinese market, commodity called gleevec, used in the treatment of chronic myelogenous leukemia zag period, accelerating period or alpha interferon treatment failure after chronic-phase; Patients with malignant gastrointestinal stromal tumors that cannot be resected or metastasized.
In April 2013, patent protection expired in China. In 2013, imatinib, a pharmaceutical group in jiangsu province, went public with a product called xinwei. In 2014, imatinii capsule, a pharmaceutical group, was listed in the company. Subsequently, the group imatinib was listed, and the commodity was named norinen.
According to the data of HDM system, the market of imatinib, a public hospital in China, was 427 million yuan in 2016, up 6.16% from the previous year. Among them, the gleevec of novartis is 83.87%, and the xinwei of jiangsu haosen is 12.31%, which is 3.63% higher than that of ganyi, and 0.19% of noliin, a stone medicine. It is expected that the domestic imatinib medicine will exceed 2 billion yuan market in 2017.
Dasatinib: fast growth potential breed
Dasatinib was a product of bristol-myers squibb, which was approved by the FDA in 2006 and is known as Sprycel. In 2011, the dachatinib tablet in bristol-myers was listed in China with the name stachai, which is used to treat patients with chronic myeloid leukemia who are resistant to imatinib or intolerance.
According to the data of HDM system, the market of dasatinib in China's key urban public hospital in 2016 was 26.45 million yuan, up 61.28% year on year, which is also a rapid growth drug, which will have great potential.
Sorafenib: the only "tini type" for liver cancer
Sorafenib is a new multitargeted anti-tumor oral drug developed by bayer and Onyx. Sorafenib was approved by the FDA in December 2005, and the product is called Nexavar. Sorafenib is the world's first approved multi-target drug, which significantly inhibits tumor angiogenesis and tumor cell proliferation. In September 2006, the CFDA approved the registration of sorafenib from Bayer Schering Pharma AG, which is known as dorje.
Ill beauty are suitable for not surgery or distant metastasis of liver cancer and metastatic renal cell of kidney cancer, local recurrence or metastasis, gradually differentiated thyroid cancer, is currently the only can be used in the treatment of small liver cancer molecular targeted drugs, and in non-small cell lung cancer, breast cancer, and other fields also have certain application prospect.
In 2016, China's key urban public hospital sorafenib market was 1.613.8 billion yuan, up 7.94 percent year on year. The market for kidney cancer has increased in recent years as Pfizer's small molecular-targeted agents, sunitinib and alcetini, have been used to treat kidney cancer in China.
Figure 5. The market value of sorafenib in key urban public hospitals in 2008-2016
After the price negotiation, sorafenib (200mg x 60) was reduced by 47.70 percent to 1,180 yuan, down from 2,280 yuan, which was the lowest price before the negotiation. At present, the friends of qilu pharmaceutical medicine, chongqing pharmaceutical, howson pharmaceutical industry in jiangsu, shandong rossing pharmaceutical, furen pharmaceutical co., chongqing st cfna, pharmaceutical technology in pharmaceutical industry, nolato, group, hunan koren pharmaceutical generic products are developing sorafenib. Sorafenib will become the driving force for the listing of domestic drugs.
Apatinib: the price of the three products is down by an average of 37%
Jiangsu hengrui self-developed country 1.1 class new medicine, "for" path mesylate in November 3, 2014 CFDA new drug certificate and production approval, issued by the commodity name YiTan, this is in the domestic field of anti-tumor and made a major breakthrough. In 2016, the apatinib market in China's key urban public hospitals was 69.15 million yuan, up 18.37 percent year on year. Apatinib has added new vitality to the targeted drug treatment market for advanced gastric cancer, which has been a bottleneck in market growth before, so price negotiations are the only breakthrough.
Drug price negotiations, according to the results of the path for his piece of three kinds of specifications (250 mg, 375 mg, 425 mg) by negotiation before bid the lowest price of 2142.40 yuan, 4534.80 yuan and 2921 yuan fell to 1360 yuan, 1855 yuan and 2858.10 yuan, the average decline of 36.99%, in 2018 a comprehensive spread the market volume has been follow.
Lapatinib: more than 200 percent growth in 2016
For lapa is developed by Britain's glaxosmithkline, belong to those who can simultaneously targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) small molecule kinase inhibitors. In March 2007, the FDA approved a listing for advanced or metastatic breast cancer. In 2013, glaxo's lapatinib was listed in China, with the name of tailisha. Clinical use of HER2 overexpression and has been used for advanced or metastatic breast cancer including anthracyclines, paclitaxel and trastuzumab.
In 2016, the market of lapatinib, a public hospital in China's major cities, was 15.69 million yuan, up 211.31 percent from the previous year, which is a small molecular targeted drug with high growth rate. The drug price negotiations showed that lapatinib tablets (250mg x 70) had been reduced by 41 per cent to 4,900 yuan, down from 8,300 yuan at the lowest price before the negotiations. Nanjing pioneers, sichuan coren, qilu pharma, zhengda tianqing pharmaceutical co., shandong luxin pharmaceutical co., LTD. Have been fighting for the development of generic drugs. |
